AI Article Synopsis
- This text discusses an innovative approach to designing clinical studies that prioritizes cost-effectiveness.
- The proposed method focuses on minimizing costs related to resources and potential study failures during early phase trials.
- By using data from a prior pharmacokinetic analysis, the design aims to achieve a specific target concentration in participants, effectively balancing expenditure and success rates in the study.
Article Abstract
We present an initial exploration of a fully cost-driven design. A design criterion was proposed that represented the minimum expected cost of an early phase clinical study, where costs include resource use as well as study failure. The design was based on attainment of a target concentration in a cohort of study participants. The model and parameter values arose from a previous population pharmacokinetic analysis of a phase I study. The resulting design naturally balanced the cost and the success rate of an early phase clinical study, without the need to define arbitrary constraints on the design space.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10543406.2016.1148703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!